2.74
-0.08(-2.84%)
Currency In USD
| Previous Close | 2.82 |
| Open | 2.82 |
| Day High | 2.82 |
| Day Low | 2.65 |
| 52-Week High | 9.55 |
| 52-Week Low | 2.65 |
| Volume | 414,575 |
| Average Volume | 365,893 |
| Market Cap | 151.62M |
| PE | -1.81 |
| EPS | -1.51 |
| Moving Average 50 Days | 3.31 |
| Moving Average 200 Days | 5.22 |
| Change | -0.08 |
If you invested $1000 in Voyager Therapeutics, Inc. (VYGR) since IPO date, it would be worth $154.37 as of June 01, 2025 at a share price of $2.74. Whereas If you bought $1000 worth of Voyager Therapeutics, Inc. (VYGR) shares 5 years ago, it would be worth $224.04 as of June 01, 2025 at a share price of $2.74.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication
GlobeNewswire Inc.
May 15, 2025 11:00 AM GMT
LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demon
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting
GlobeNewswire Inc.
Apr 28, 2025 8:30 PM GMT
- Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of 1.3e13 vg/kg - - Featured data also include anti-amyloid gene therapy for Alzheimer’
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
GlobeNewswire Inc.
Mar 31, 2025 11:00 AM GMT
- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specifically targeti